Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,015
  • Shares Outstanding, K 12,237
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,210 K
  • EBIT $ -59 M
  • EBITDA $ -61 M
  • 60-Month Beta 3.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.81

Options Overview Details

View History
  • Implied Volatility 127.86% ( +2.83%)
  • Historical Volatility 73.14%
  • IV Percentile 73%
  • IV Rank 34.37%
  • IV High 248.58% on 02/10/25
  • IV Low 64.65% on 11/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 1,188
  • Open Int (30-Day) 1,102

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.55
  • Number of Estimates 8
  • High Estimate -0.89
  • Low Estimate -2.99
  • Prior Year -0.90
  • Growth Rate Est. (year over year) -72.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.72 +26.49%
on 07/01/25
8.85 -3.95%
on 07/17/25
+0.19 (+2.29%)
since 06/18/25
3-Month
5.90 +44.07%
on 04/21/25
9.45 -10.09%
on 06/09/25
+2.47 (+40.96%)
since 04/17/25
52-Week
4.64 +83.19%
on 04/07/25
61.90 -86.27%
on 07/31/24
-44.53 (-83.97%)
since 07/18/24

Most Recent Stories

More News
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX : 1.1300 (unch)
QURE : 14.99 (-1.38%)
CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals: Q1 Earnings Snapshot

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRBP : 8.50 (+0.47%)
Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals: Q4 Earnings Snapshot

CRBP : 8.50 (+0.47%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 9.05
2nd Resistance Point 8.94
1st Resistance Point 8.72
Last Price 8.50
1st Support Level 8.38
2nd Support Level 8.27
3rd Support Level 8.05

See More

52-Week High 61.90
Fibonacci 61.8% 40.03
Fibonacci 50% 33.27
Fibonacci 38.2% 26.51
Last Price 8.50
52-Week Low 4.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar